(Q70501182)

English

Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy

scientific article published on 01 January 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

Renal, metabolic, and hemodynamic side-effects of interleukin-2 and/or interferon alpha: evidence of a risk/benefit advantage of subcutaneous therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

author name string

A Schomburg

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

H Kirchner

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

J Atzpodien

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

publication date

1 January 1993

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

119

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

745-755

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

https://scigraph.springernature.com/pub.10.1007/bf01195347

0 references

Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term cultures of human peripheral blood lymphocytes with recombinant human interleukin-2 generate a population of virtually pure CD3+CD16-CD56- large granular lymphocyte LAK cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon treatment of renal cell carcinoma. Current status and future prospects

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 induces profound reversible cholestasis: a detailed analysis in treated cancer patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiopulmonary toxicity of adoptive immunotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 therapy for advanced renal cell carcinoma: radiographic evaluation of response and complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of weekly 24-hour infusions of recombinant human interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical effects and toxicity of interleukin-2 in patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of lymphokine-activated killer induction by neutrophils

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The human lymphokine-activated killer cell system. V. Purified recombinant interleukin 2 activates cytotoxic lymphocytes which lyse both natural killer-resistant autologous and allogeneic tumors and trinitrophenyl-modified autologous peripheral bloo

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunomodulatory and immunotherapeutic properties of recombinant gamma-interferon and recombinant tumor necrosis factor in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular leak syndrome associated with interleukin-2: chest radiographic manifestations

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 immunotherapy in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 initiates metabolic responses associated with critical illness in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon therapy for renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nephrotic syndrome associated with recombinant interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in laboratory results for cancer patients treated with interleukin-2

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of interleukin-2 immunotherapy on renal function

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal effects of continuous infusion of recombinant interleukin-2 in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiorespiratory effects of immunotherapy with interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant gamma-interferon.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myocardial toxic effects during recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal, volume, and hormonal changes during therapeutic administration of recombinant interleukin-2 in man.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8408187

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01195347

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8408187%20AND%20SRC:MED&resulttype=core&format=json

11 October 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q70501182&oldid=2123945440"